In this issue:
Bionic pancreas in type 1 diabetes
Glycaemia reduction in type 2 diabetes: glycaemic, microvascular and CV outcomes
Advanced hybrid closed-loop therapy for type 1 diabetes
Global incidence, prevalence and mortality of type 1 diabetes out to 2040
Risk factors, mortality trends and CV diseases in type 1 diabetes
Tirzepatide vs. glargine: kidney outcomes in type 2 diabetes
Modifiable risk factors and longterm type 2 diabetes risk after GDM
Association of GDM with overall and type-specific CV/cerebrovascular diseases
Lifetime risk, life expectancy and years of life lost to type 2 diabetes in high-income jurisdictions
Please login below to download this issue (PDF)